The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials

被引:11
|
作者
Manning-Bennett, Arkady T. [1 ]
Hopkins, Ashley M. [2 ]
Sorich, Michael J. [2 ]
Proudman, Susanna M. [3 ,4 ]
Foster, David J. R. [1 ]
Abuhelwa, Ahmad Y. [2 ,5 ]
Wiese, Michael D. [1 ]
机构
[1] Univ South Australia, UniSA Clin & Hlth Sci, North Terrace, Adelaide, SA 5000, Australia
[2] Flinders Univ S Australia, Coll Med & Publ Hlth, Discipline Clin Pharmacol, Bedford Pk, SA, Australia
[3] Royal Adelaide Hosp, Rheumatol Unit, Adelaide, SA, Australia
[4] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[5] Univ Sharjah, Coll Pharm, Sharjah, U Arab Emirates
关键词
anxiety; depression; Rheumatoid arthritis; remission; tocilizumab; MODIFYING ANTIRHEUMATIC DRUGS; DISEASE-ACTIVITY INDEX; BRITISH ASSOCIATION; AMERICAN-COLLEGE; PREVALENCE; ANTIDEPRESSANTS; TOCILIZUMAB; COMBINATION; DEFINITION; GUIDELINES;
D O I
10.1177/1759720X221111613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rheumatoid arthritis (RA) is an inflammatory autoimmune condition associated with an increased risk of developing depression and anxiety. Depression and anxiety are associated with worse outcomes in RA, but the magnitude of the effect of each condition on RA outcomes is unclear. It is also unknown how pharmacological treatment of depression affects RA outcomes. Objective: The primary aim of this study was to investigate the association of comorbid depression and anxiety with remission in patients with RA. Secondary aims were to determine the association between comorbid depression and anxiety on patient-reported outcomes and the relationship between concomitant use of antidepressants and remission in patients with depression. Design: Data from patients with moderate to severe RA were pooled from five randomised controlled trials investigating tocilizumab and conventional synthetic disease-modifying agents. Methods: Remission was defined as a clinical disease activity index (CDAI) of <= 2.8 and simple disease activity index (SDAI) of <= 3.3. The association between the time to reach remission and depression and anxiety was analysed using Cox proportional hazard analysis. Results: Individual patient data were available from 5502 subjects, of whom 511 had depression, 236 had anxiety and 387 were using antidepressants. Depression was significantly associated with reduced remission [adjusted HR (95% CI): 0.62 (0.48-0.80), p < 0.001 and adjusted HR (95% CI): 0.59 (0.44-0.79), p < 0.001] using CDAI and SDAI, respectively. Depression was associated with a lower likelihood of achieving more subjective outcomes (<= 1 physician global assessment, <= 1 patient global assessment) and <= 1 28-swollen joint count, but not <= 1 28-tender joint count or C-reactive protein measurement. Treatment with antidepressants did not improve outcomes for patients with depression. Anxiety was not significantly associated with RA remission. Conclusion: Comorbid depression, but not anxiety, was associated with less frequent remission. Concomitant antidepressant use was not associated with improvements in RA outcomes in patients with depression.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials
    Smolen, Josef S.
    Beaulieu, Andre D.
    Dikranian, Ara
    Fenton, Ira
    Fisheleva, Elena
    Alecock, Emma
    Emery, Paul
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S784 - S784
  • [2] Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials
    Law-Wan, Johan
    Sparfel, Marc-Antoine
    Derolez, Sophie
    Azzopardi, Nicolas
    Goupille, Philippe
    Detert, Jacqueline
    Mulleman, Denis
    Bejan-Angoulvant, Theodora
    RMD OPEN, 2021, 7 (03):
  • [3] DEPRESSION AND ANXIETY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Katchamart, Wanruchada
    Narongroeknawin, Pongthorn
    Chanapai, Wanwisa
    Thaweeratthakul, Phakhamon
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1623 - 1623
  • [4] Anxiety and depression in patients with rheumatoid arthritis
    Ahmet Isik
    Suleyman Serdar Koca
    Abdullah Ozturk
    Osman Mermi
    Clinical Rheumatology, 2007, 26 : 872 - 878
  • [5] Anxiety and depression in patients with rheumatoid arthritis
    Isik, Ahmet
    Koca, Suleyman Serdar
    Ozturk, Abdullah
    Mermi, Osman
    CLINICAL RHEUMATOLOGY, 2007, 26 (06) : 872 - 878
  • [6] DEPRESSION AND ANXIETY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Ibarra, Bruno
    Roman, Lourdes
    Valinotti, Vannia
    Paats, Astrid
    Acosta, Rodrigo
    Riquelme, Susan
    Coronal, Johana
    Pineda, Alexis
    Leiva, Evelyn
    Cabrera, Sonia
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S98 - S99
  • [7] Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials
    Tanaka, Yoshiya
    Yamanaka, Hisashi
    Toyoizumi, Shigeyuki
    Hirose, Tomohiro
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2025,
  • [8] Hepatic aminotransferases and bilirubin levels during tocilizumab treatment of patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials
    Kremer, Joel M.
    Joh, Ani K.
    Malamet, Raymond
    Keystone, Ed C.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S783 - S783
  • [9] Hepatic Aminotransferases and Bilirubin Levels During Tocilizumab Treatment of Patients with Rheumatoid Arthritis: Pooled Analysis of Five Phase 3 Clinical Trials
    Bykerk, Vivian P.
    Kremer, Joel M.
    Keystone, Edward C.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2591 - 2591
  • [10] Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis
    Baron, Gabriel
    Boutron, Isabelle
    Giraudeau, Bruno
    Ravaud, Philippe
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (05) : 651 - 657